Full Press Release Details
New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes
NEW YORK, May 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital health interventions to drive flu vaccine awareness in Dario members living with diabetes.
People living with diabetes are at risk of severe complications from the flu, yet low awareness keeps many from receiving an influenza vaccination. To better understand how digital health tools could raise awareness and improve vaccination rates in this population a pragmatic randomized follow-up study was performed using Dario's digital health solution for diabetes management which delivers a highly personalized, whole health approach to help members improve overall health and outcomes. The study also aimed to highlight the effectiveness of personalizing digital interventions to positively impact member engagement and behavior change.
A previous randomized controlled study ("RCT") proved the effectiveness of a nudge intervention to improve vaccination rates, and Dario's study's was designed as a pragmatic follow-up to translate the initial insights into a real-world setting. To accomplish this, the research team leveraged Dario's capabilities around personalization to deliver tailored messaging across a large data set of 64,904 members segmented into three groups: first, a group of members with exposure to a monthly flu vaccination campaign previously proven to impact vaccination rates; second, a group of members receiving an adapted version of the same campaign with more personalized and frequent messages; and third, a control group with no exposure to flu vaccination messages.
The results showcase the power of personalized digital health interventions with the second group demonstrating significantly improved awareness of the risks associated with the flu and higher rates of vaccination than the group receiving the messages previously tested in the RCT.
"At Dario, we're constantly striving to deepen member engagement through personalized, meaningful interventions that drive real outcomes," said Yifat Hershcovitz, PhD, Vice President of Clinical and Scientific Affairs at Dario. "This study highlights how our personalization engine can deliver measurable clinical impact. By helping members better understand their health and take action, such as avoiding severe flu-related complications, we believe that Dario is able to improve both individual well-being and client outcomes."
"Digital health creates powerful opportunities to engage people and change behaviors in meaningful ways. This study adds to the growing body of evidence showing how solutions like Dario can drive real clinical outcomes," said Omar Manejwala, M.D., Chief Medical Officer at Dario. "We believe deeply in the power of personalization to improve health, and we're proud to have our work featured in JMIR—a recognition of the science behind Dario's approach to transforming care through digital innovation."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the deepening member engagement through personalized, meaningful intervention through the Company's platform; the Company's ability to improve both individual well-being and client outcomes through its platform; and that the Company's approach can transform care through digital innovation. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
DarioHealth Investor Relations Contact
Investor Relations Manager
